View profile

FarmaKology Newsletter - Issue #44

Revue
 
Would you like to submit an article, some interesting news, or get your startup featured? Send whatev
 

FarmaKology

May 13 · Issue #44 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+4900 Subscribers ) !

Codiak BioSciences
Codiak BioSciences
Today's Startup
Codiak BioSciences
Codiak BioSciences is harnessing exosomes—natural intercellular messengers—to pioneer a new class of biologic medicines, exosome therapeutics. We have developed the engExTM Platform, our proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutic candidates. Using our engEx Platform, we can engineer exosomes to have precise and intentionally chosen properties, to incorporate various forms of biologically active molecules, including small molecules, nucleic acids, proteins, antibodies, enzymes, cytokines and complex ligands, with the goal of delivering potent signals to specific cell targets.
News
Amorepacific, Korea’s leading beauty company, officially unveiled its Lab Tailored 3D Mask from IOPE, the company’s skincare brand known for scientifically produced products. A 2020 CES Innovation Award honoree, the Lab Tailored 3D Mask is a made-to-measure hydrogel mask created with the company’s own innovative 3D mask printing technology to fit each person’s individual facial dimensions and skin conditions.
The US Food and Drug Administration has awarded fast track designation to Moderna mRNA vaccine candidate, mRNA-1273, developed to protect against Covid-19.Fast track designation enables development and speed-up of the review of therapies and vaccines that target serious conditions and fill an unmet medical need.Programmes with the designation could see early and frequent communication with the FDA , along with a rolling submission of the marketing application.
Cipla Limited today announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients. This agreement is part of Cipla’s efforts to enhance global access to life-saving treatments for patients affected by the pandemic.
The US Food and Drug Administration (FDA) on Monday evening issued two guidances intended to accelerate the development of products to treat or prevent coronavirus disease (COVID-19), laying out recommendations to help companies get to the investigational new drug application (IND) stage and clinical trial design considerations for later-stage studies.
Research & Study
Podcast
Episode 110: Pandemic projections, Gilead's pricing dilemma & fighting Covid-19 in New York by STAT | Free Listening on SoundCloud
Job Opportunities
Upcoming Webinar
Video
Webinar: Big Data and Analytics in Pharma
FarmaKology
FarmaKology
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue